After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We are very excited to launch our new website! Please take a few moments to click around and explore...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...